Lorenzo Gerratana

Out in @eClinicalMed a network M-A evaluating treatment strategies after PD on CDK4/6i in HR+/HER2− mBC Results support biomarker-driven algorithm and are relevant since head-to-head trials are unlikely to be conducted! Congrats @RobertoBuonaiu3 @CarmineDeA1 👏 @OncoAlert

🏅Optimal treatment sequencing after CDK4/6i + ET in HR+/HER2− MBC remains unclear due to lack of head-to-head trials 🤔 💻We conducted a systematic review & NMA to guide evidence-based decisions. 📰Read more: authors.elsevier.com/sd/article/S25… @OncoAlert @oncodaily @eClinicalMed

Just wrapped up the 2025 GIM annual meeting Proud of our fellows and postdocs who blew us away with exciting new trial ideas: the #NextGeneration of #oncology #research is already here. #GIM #liquidbiopsy #PrecisionMedicine

Riunione annuale GIM – Gruppo Italiano Mammella 📍 Domani 26 e 27 settembre a Bergamo. Il #GIM è uno dei principali consorzi indipendenti per la ricerca sul carcinoma mammario, con oltre 150 centri e 500 sperimentatori coinvolti. L’appuntamento annuale è un momento chiave per condividere risultati, aggiornarsi sui trial in corso e proporre nuovi studi, favorendo confronto e networking tra i maggiori esperti e giovani ricercatori del settore. Responsabili Scientifici: Alberto Zambelli, Armando Santoro. Comitato organizzatore: @arpino_grazia, @delmastro_lucia, Michelino De Laurentiis @MicheleDelauren, Sabino De Placido, Alessandra Fabi, @puglisi_fabio. 👉 Guarda il programma: overgroup.eu/evento/gim-gru… #GIM #BreastCancer #Oncologia #ClinicalResearch

New Study 👉Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive #MetastaticBreastCancer: A biomarker analysis from the PACE phase II study. #ctDNA #MNC #BreastCancer 📎pubmed.ncbi.nlm.nih.gov/40853871/ @LGerratana @ReduzziCarol @RMJesel @AngieDemichele @jane_meisel @YAbdouMD @KUMedCenter @NaomiKoMD @DrHBurstein @MKDeMeo @stolaney1 @elmayermd

Treatment impact adjusted for clinical + ESR1, RB1, PIK3CA ctDNA: Stage IV aggressive ▪️ F+P HR 0.39 ▪️ F+P+A HR 0.19 Stage IV indolent ▪️ F+P HR 1.17 ▪️ F+P+A HR 0.99 Interaction p=0.0148 & 0.0033

🧬 Patients with Stage IV aggressive disease had a higher prevalence of ESR1 and RB1 mutations, while no difference were observed for PIK3CA 🔹 ESR1 → 62.6% vs 41.3% (p=0.0008) 🔹 RB1 → 18.2% vs 4.8% (p=0.0031)

Biomarker analysis of the PACE trial in HR+/HER2– #metastatic #breastcancer after CDK4/6i: ‼️Baseline #CTC enumeration (≥5 CTCs) identifies patients with extended PFS from F+palbociclib (F+P) or F+P+avelumab vs fulvestrant (F) alone. 👉🧵 A thread doi.org/10.1158/1078-0…

Mark your calendar for the International Inflammatory Breast Cancer Symposium! 🗓️ October 23, 2025 📍 Milan (Italy) 🌐 Join in person or online Don’t miss this opportunity to connect with global IBC experts, share ideas, and advance research to improve patient outcomes.

Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER) buff.ly/UrXfLEu In this open-label, phase II trial of pretreated HER2-positive advanced #BreastCancer , trastuzumab plus lapatinib (with endocrine therapy for hormone receptor-positive patients) was compared to trastuzumab with physician-selected chemotherapy in 59 patients who had received at least two prior anti-HER2 regimens. Although the chemotherapy arm showed slightly better clinical benefit rate (26.7% vs. 20.7%), progression-free survival (6.1 vs. 3.6 months), and overall response rate, none of these differences reached statistical significance, and overall survival was nearly identical between arms. Adverse events were more frequent and severe in the lapatinib group, yet this arm was associated with better quality of life. These findings, though exploratory due to early study closure and limited sample size, suggest that trastuzumab plus lapatinib could be a tolerable, chemotherapy-free alternative in select patients prioritizing quality of life. @CarmineDeA1 @marti_pagliuca @Roberta27585687 @SCinieri @alessandrafab11 @delmastro_lucia @puglisi_fabio @arpino_grazia Breast @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @stolaney1 @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @itrisabel #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua

Can #fragmentomics become a new monitoring #biomarker in metastatic breast cancer? 🔬 👉 Here we explore a mutation-agnostic, cost-effective approach tested in the MAGNETIC.1 trial—a longitudinal study of first-line HR+/HER2- MBC. doi.org/10.1016/j.tran…

📢 Just out on @CROH our Italian Delphi consensus 🤝🏻on the evolving landscape of HR+/HER2- mBC (EVOLVE). 💊Resistance/sensitivity to CDK4/6i+ET 🧬Biomarkers 🔎Treatment algorithm 📃: doi.org/10.1016/j.crit… Proud to be part of this huge national effort.

It’s an honor and an incredible opportunity to be part of this project! Looking forward to diving into #liquidbiopsy and treatment resistance in ER+/HER2- metastatic #breastcancer. 📅 June 11, 2:00pm EDT Join us! 👇 #ASCO25 #bcsm #GRASPPosters #GRASPatASCO #MBC #ctDNA

Join UNC's Assistant Professor of Medicine @YAbdouMD on June 12 as she discusses racial inequities and HER2-Negative breast cancer. This group will fill up fast, so make sure you register today graspcancer.org/events/asco25-… #asco2025 #bcsm #registertoday #GRASPPosters #GRASPatASCO

Join Mentor @JaniceTNBCmets on Wednesday, June 12 at 2:00 pm as she leads the discussion on Triple-Negative Breast Cancer and Antibody-Drug Conjugates (ACDs). These sessions fill up fast, so register today! graspcancer.org/events/asco25-… #asco #asco2025 #bcsm #registertoday

Join GRASP Scientist Jennifer Sheng, M.D., as we discuss alcohol intake and health-related quality of life in breast cancer survivors, and alcohol intake. Join us on June 11 for a deeper into these topics and discuss Posters. graspcancer.org/events/asco25-… #bcsm #GRASPPosters #alcohol

Really grateful for another successful #YBO event in beautiful #genova…definitely a bright future ahead for 🇮🇹 with such an excellent and motivated young #BreastCancer community ❤️🤩🔝💪 @UniGenova @SanMartino_Ge @Lucarecco @OncoAlert

Couldn’t make it to the packed #ASCO25 session? Join @GRASPtweets next week for a small-group discussion on the #DESTINYBreast09 practice-changing data showing Enhertu's potential in earlier-line HER2+ MBC. Register at tinyurl.com/27c83p3v #bcsm

DESTINY-B09 at #ASCO25: ✅ T-DXd + P improved PFS vs THP (40.7 vs 26.9 mo; HR 0.56) 🔭 Benefit consistent across subgroups, incl. PIK3CA mut/wt #MBC ⏱️ ORR 85% with durable responses ⏳ ~16–20% maturity for OS/PFS2 – further follow-up awaited Is there room for maintenance?

SERENA6 at #ASCO25: A crucial step for clinical utility of #liquidbiopsy ⏱️ Switching to camizestrant + CDK4/6i upon pre-progression detection of #ESR1 mut in #ctDNA improved PFS1(16.0 vs 9.2 mo; HR 0.44). 🧪 PFS2 showed a promising early signal (HR 0.52) although not mature